This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Sara Colombetti, PhD
Global Head of Oncology Discovery Pharmacology at Roche Innovation Center Zürich
Speaker

Profile

In 2004 I received my Ph.D. in Molecular and Cellular biology at the San Raffaele Scientific Institute in Milan (Italy). After a post-doc in cancer immunotherapy at the Ludwig Institute for Cancer Research (Lausanne branch) and later at Cytos Biotechnology (Zurich) I have joined the Roche Innovation Center Zurich (RICZ) in 2009, where I initially led the In Vivo Models team and then the Immuno-Pharmacodynamics and PK Unit. In 2018 I have been appointed Global Head of Oncology Discovery Pharmacology, a global group with teams in Switzerland, Germany and France. The group is part of the Oncology Discovery Unit within the Roche pharma Research and Development (pRED) division. The focus of the group is the development of cutting edge preclinical models for the evaluation of all pRED Oncology portfolio assets.

Agenda Sessions

  • Co-Chairs’ Remarks - Forward and Reverse Translation in Antibody Research

    2:25pm
  • CD19 Targeted CD28 Agonism: Learnings from Forward and Reverse Translation Approaches

    5:45pm